ACE
ACE plays a central role in blood pressure regulation by converting angiotensin I to the potent vasoconstrictor angiotensin II. It is the direct target of ACE inhibitors, one of the most widely prescribed drug classes for hypertension and heart failure.
Key Takeaways
- •ACE is the master enzyme of the Renin-Angiotensin-Aldosterone System (RAAS).
- •It converts inactive Angiotensin I into the powerful vasoconstrictor Angiotensin II.
- •ACE also degrades bradykinin, a natural vasodilator, further increasing blood pressure.
- •Common genetic variants (ACE I/D) significantly influence circulating enzyme levels and cardiovascular risk.
Basic Information
- Gene Symbol
- ACE
- Full Name
- Angiotensin I Converting Enzyme
- Also Known As
- CD143DCPDCP1
- Location
- 17q23.3
- Protein Type
- Metalloproteinase
- Protein Family
- M2 family of dipeptidyl carboxypeptidases
Related Isoforms
Key SNPs
The famous I/D (Insertion/Deletion) polymorphism. Deletion (D) allele carriers have higher circulating ACE levels and increased risk for hypertension and left ventricular hypertrophy.
Overview
The ACE gene encodes angiotensin-converting enzyme, a zinc-binding metalloproteinase found primarily on the surface of vascular endothelial cells, especially in the lungs. It is the terminal enzyme in the canonical RAAS pathway, which is the body’s primary mechanism for maintaining blood pressure and fluid balance.
ACE has two main substrates: it cleaves two amino acids from the decapeptide Angiotensin I to produce the octapeptide Angiotensin II, and it inactivates the vasodilator bradykinin. By simultaneously increasing a vasoconstrictor and decreasing a vasodilator, ACE serves as a potent driver of systemic vascular resistance and salt retention.
Conceptual Model
A simplified mental model for the pathway:
ACE is the definitive valve that increases the "pressure" in the cardiovascular system.
Core Health Impacts
- • Blood pressure: The master systemic regulator of vascular tone and resistance.
- • Fluid balance: Controls sodium retention and water volume via the RAAS axis.
- • Cardiac remodeling: Chronic Ang II production drives fibrosis and stiffening of the heart muscle.
- • Renal function: Regulates glomerular filtration pressure and long-term kidney health.
Upstream Regulators
Renin Activator
The rate-limiting enzyme that provides the Angiotensin I substrate for ACE.
Hypoxia Activator
Low oxygen levels in the lungs and kidneys can upregulate ACE expression.
Sympathetic Nervous System Activator
Fight-or-flight signaling drives the entire RAAS cascade starting with renin.
ACE Inhibitors Inhibitor
Competitive inhibitors that physically block the enzyme’s catalytic site.
Downstream Targets
Angiotensin II Activates
The primary active product; causes vasoconstriction and inflammation.
Bradykinin Inhibits
A vasodilator that is rapidly degraded and inactivated by ACE.
Aldosterone Activates
Indirect target; Ang II stimulates its release from the adrenal glands.
AGTR1 Activates
Ang II binds this receptor to mediate almost all of its pathological effects.
Role in Aging
The RAAS system, and ACE in particular, becomes progressively overactive with age, contributing to the "stiffening" of the vascular tree and the development of age-related hypertension.
Vascular Stiffness
Chronic exposure to Ang II (via ACE) drives the cross-linking of collagen in artery walls, leading to increased pulse wave velocity and stiffening.
Inflammaging
Ang II is a pro-inflammatory peptide that stimulates NF-κB, linking ACE overactivity directly to age-related low-grade systemic inflammation.
Renal Aging
Progressive ACE activity contributes to the gradual decline in glomerular filtration rate (GFR) seen in the elderly.
Centenarian Genetics
The "I" (Insertion) allele, which correlates with lower ACE levels, is often found to be enriched in exceptionally long-lived populations.
Disorders & Diseases
Hypertension
ACE overactivity is a primary driver of essential hypertension. ACE inhibitors are first-line therapy.
Heart Failure
In heart failure, the RAAS system is maladaptively activated; blocking ACE prevents pathological cardiac remodeling and reduces mortality.
Diabetic Nephropathy
High intra-renal ACE activity damages the filters of the kidney in diabetes; ACE inhibitors are "kidney protective."
Left Ventricular Hypertrophy
The ACE "D" allele is a known genetic risk factor for the pathological thickening of the heart wall.
Interventions
Supplements
Contains bioactive sulfur compounds that demonstrate mild ACE-inhibiting properties in clinical trials.
Peptides found in fermented dairy (VPP and IPP) that act as natural competitive ACE inhibitors.
Rich in anthocyanins that have been shown to lower blood pressure with efficacy comparable to mild ACE inhibitors.
Lifestyle
Reducing salt intake lowers the systemic pressure, though it can paradoxically trigger a compensatory rise in ACE activity.
Visceral fat contains its own local RAAS; losing weight reduces the total systemic "dose" of ACE.
High dietary potassium antagonizes the effects of the RAAS system and helps blunt the action of ACE.
Medicines
Classic ACE inhibitors that lower blood pressure and protect against heart failure and kidney disease.
Angiotensin Receptor Blockers (ARBs) that block the receptor (AGTR1) downstream of ACE.
Aldosterone antagonist used to block the final stage of the ACE-driven salt retention cascade.
Lab Tests & Biomarkers
Activity Markers
Measured primarily to screen for sarcoidosis, where levels are massively elevated.
Measures the "spark" that precedes ACE action; helps classify types of hypertension.
The primary clinical biomarker for the integrated activity of the ACE/RAAS pathway.
Hormonal Interactions
Angiotensin II Primary Product
The potent vasoconstrictor produced directly by ACE action.
Aldosterone Downstream Effector
Hormone from the adrenal cortex that sponges up salt in response to ACE-produced Ang II.
Renin Upstream Starter
The kidney enzyme that starts the cascade by producing the precursor for ACE.
Deep Dive
Network Diagrams
The ACE / RAAS Cascade
RAAS Feedback Control
Activation Mechanics: The Zinc-Dependent Cleaver
ACE is a type I transmembrane protein that functions as a carboxymonopeptidase and a carboxydipeptidase. It is essentially a pair of molecular scissors specialized for removing amino acids from the tails of peptides.
The catalytic core of ACE requires a zinc ion to function. In the canonical RAAS pathway, ACE cleaves the two C-terminal amino acids (His-Leu) from the inactive decapeptide Angiotensin I. This conversion produces the highly potent octapeptide Angiotensin II. Because Angiotensin II is thousands of times more powerful than its precursor at constricting arteries, the ACE enzyme acts as the critical amplifier of the entire blood pressure signal.
Dual-Action Blood Pressure Driver
What makes ACE uniquely powerful is that it targets two opposing sides of the vascular balance sheet simultaneously.
- The Pressor Side: By producing Angiotensin II, ACE drives vasoconstriction, inflammation, and salt retention (via aldosterone).
- The Depressor Side: ACE also recognizes and degrades bradykinin, a natural peptide that keeps blood vessels relaxed and open.
By increasing the “gas” (Ang II) while removing the “brakes” (bradykinin), ACE is the body’s most effective mechanism for raising systemic pressure. This dual role also explains the most common side effect of ACE inhibitors: the dry “ACE cough.” By blocking the enzyme, bradykinin levels rise in the lungs, where it can irritate sensory nerves.
The ACE I/D Polymorphism: Genetic “Volume” Control
The ACE gene contains a famous genetic variant consisting of the presence (Insertion, I) or absence (Deletion, D) of a 287-base pair segment in an intron.
This variant acts like a volume knob for the ACE enzyme. Individuals with the DD genotype have roughly twice the level of circulating ACE protein as those with the II genotype. Over a lifetime, this higher enzyme “dose” means higher average Angiotensin II levels, contributing to an increased risk of high blood pressure, heart wall thickening (hypertrophy), and age-related kidney decline.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The definitive trial proving that blocking the ACE pathway extends human life in the setting of heart failure.
Confirmed the significant link between the ACE I/D genotype and hypertension risk.